FDA Advisory Committee Recommends against Bevacizumab for Metastatic Breast Cancer

July 20, 2020

By National Cancer Institute

On July 20, the Oncologic Drugs Advisory Committee (ODAC) of the FDA’s Center for Drug Evaluation and Research voted 12 to 1 to recommend against the use of bevacizumab (Avastin) in combination with chemotherapy for the first-line treatment of metastatic breast cancer

Welch lends breast-cancer expertise to scientific council

July 13, 2020

By University of Alabama - UAB Online

Danny Welch, Ph.D., is a senior scientist in the UAB Comprehensive Cancer Center and a renowned expert in the biology and genetics of cancer metastasis - the process by which cancer cells break away from a primary tumor and enter the bloodstream or lymphatic system and spread to other parts of the body.

Metastases Kills 90 Percent Of All Cancer Patients But Only Five Percent Of Cancer Research Funds Are Spent On It

July 12, 2020

By Medical News Today

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC). [1]

NHS regulator rejects breast cancer treatment

July 9, 2020

By Nicky Broyd, WebMD Health News

9th July 2010 — In draft guidance issued today by the National Institute for Health and Clinical Excellence (NICE), the drug bevacizumab (Avastin) is not recommended for use in combination with a taxane for patients whose breast cancer has spread to other parts of the body.